Plain-English translation of NCT07414212 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a combination of N- (NAC) and EH-301, taken together with (a standard ALS medication), can help slow down or improve symptoms of ALS. Researchers will measure how the treatment affects your daily functioning and ability to move over a 6-month period. Half of participants will receive the active medication combination, while the other half will receive placebo pills that look identical.
ALS is a serious disease that causes progressive weakness, and current standard treatment is limited. Researchers are investigating whether this medication combination might offer additional benefit beyond the standard treatment alone.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly over 6 months for check-ups, safety tests, and measurements of how your ALS is progressing. You will randomly receive either the active medication combination or placebo pills (along with your regular dose), and neither you nor the doctors will know which group you're in. After the initial 6 months, you'll have the option to continue for another 6 months, during which everyone receives the active treatment.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Spain